Follow the Money to Medical Device & Diagnostic Opportunities
Spotlight on EndoStim, Inc.

by

Follow the Money to Medical Device & Diagnostic Opportunities highlights a newly funded medical device or diagnostic company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities.

EndoStim, Inc. is a private US company that develops neurostimulation devices for the treatment of neuromuscular disorders. It has raised $25 million in a completion of a venture capital investment, as reported in the PharmSource Lead Sheet on May 19, 2016.

Corporate Highlights

  • EndoStim was incorporated in Delaware in 2009.
  • Corporate Headquarters: St. Louis, MO – approximately 2,020 square feet
  • As of June 2014, they had 13 employees.

Sourcing Opportunities

  • EndoStim plans to use the proceeds to support a US pivotal clinical trial and global commercialization efforts for its LES stimulation system for the treatment of gastroesophageal reflux disease, and R&D of new devices.

Business Relationships

  • In March 2013, EndoStim and the Centro de Construcción (CCC) of Uruguay entered into a development and supply agreement for its neurostimulation system. CCC manufactured and developed the system while EndoStim received exclusive rights to all intellectual property, design, and test results. Financial terms were undisclosed.

Previous Financings

  • March 2016: $11 million in a completed venture capital investment
  • December 2015: EndoStim cancels a $35 million IPO
  • May 2015: $2.5 million in a completed venture capital investment
  • October 2014: EndoStim postpones its IPO
  • September 2014: EndoStim files an IPO
  • July 2014: $6.4 million in a completed venture capital investment
  • April 2013: $1.6 million in a completed venture capital investment

Medical Device & Diagnostics Pipeline1

Product Candidate Indication Medical Specialty Purpose Type
LES stimulation system Gastroesophageal reflux disease Gastrointestinal Device-Therapeutic/
Interventional
Implant-Other
Electrode/Stimulator

Regulatory Approvals and Clearances

Product Candidate Region Approval/Clearance Year of Approval or Clearance
LES stimulation system (full body MRI) Europe CE Mark approval 2015
LES stimulation system Brazil Regulatory approval 2015
LES stimulation system Mexico Regulatory approval 2015
LES stimulation system Australia TGA approval 2014
LES stimulation system Colombia Regulatory approval 2013
LES stimulation system Europe CE Mark approval 2012

1Source: PharmSource Lead Sheet

Contact Information

EndoStim, Inc. Key Officers
4041 Forest Park Avenue, Suite 220 Rohan J. Hoare, President & CEO
Saint Louis, MO 63108 USA Peggy S. Stohr, CFO
Phone: +1-314-615-6346 Paul Goode, PhD, SVP, R&D
Web: www.endostim.com Virender K. Sharma, MD, CMO

Related posts:
Follow the Money to Medical Device & Diagnostic Opportunities – Spotlight on Organogenesis, Inc.
Follow the Money: ArQule, Inc.
Follow the Money: Amarantus Bioscience Holdings, Inc.

Scotty is a Research Analyst at PharmSource. He holds a BS degree in Biology from George Mason University and an MPH degree from Eastern Virginia Medical School. He’s experienced in data collection, analysis and management, and has done laboratory analysis and safety program development.

More posts by Scotty Chung-Siu